Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid

Trial Profile

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2016

At a glance

  • Drugs Clobetasol (Primary)
  • Indications Bullous pemphigoid
  • Focus Therapeutic Use
  • Acronyms RECOPB
  • Most Recent Events

    • 30 Apr 2015 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 30 Apr 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov.
    • 30 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top